Natural History and Factors Associated with Early and Delayed Mortality in HIV-Infected Patients Treated of Tuberculosis under Directly Observed Treatment Short-Course Strategy: A Prospective Cohort Study in India

Table 1

General characteristics of the patients and the median CD4+ lymphocyte count.

	𝑁	% (95% CI)	Median CD4 count* (IQR)
Gender
Male	659	65.9 (62.9–68.8)	113 (58–183)
Female	341	34.1 (31.2–37.1)	124 (67–212)
Literacy
Yes	410	41 (38–44.1)	115 (56–188)
No	590	59 (55.9–62)	116 (65–195)
Homeless
No	954	95.4 (93.9–96.5)	115 (60–189)
Yes	46	4.6 (3.5–6.1)	133 (74–214)
Community
Scheduled tribe	77	7.7 (6.2–9.5)	115 (60–189)
Scheduled cast	235	23.5 (21–26.2)	124 (64–207)
Backward cast	490	49 (45.9–52.1)	123 (66–189)
Other casts	198	19.8 (17.4–22.4)	104 (53–181)
AFB in sputum
Negative	743	74.3 (71.5–76.9)	118 (66–194)
Positive	257	25.7 (23.1–28.5)	109 (50–181)
Previous ATT
No (category I)	794	79.4 (76.8–81.8)	115 (61–183)
Yes (category II)	206	20.6 (18.2–23.2)	126 (61–219)
Organ involved
Abdominal	117	11.7 (9.8–13.8)	117 (64–175)
Lymphadenitis	89	8.9 (7.3–10.8)	137 (74–217)
Meningitis	190	19 (16.7–21.6)	115 (64–181)
Pleuritis	174	17.4 (15.2–19.9)	132 (67–204)
Pulmonary AFB negative	137	13.7 (11.7–16)	105 (52–195)
Pulmonary AFB positive	205	20.5 (18.1–23.1)	115 (60–200)
Disseminated	63	6.3 (4.9–8)	103 (39–178)
Others	25	2.5 (1.7–3.7)	135 (84–207)
Timing of ART
Before ATT	384	38.4 (35.4–41.5)	153 (86–218)
0-1 months after ATT	176	17.6 (15.4–20.1)	103 (49–147)
1-2 months after ATT	91	9.1 (7.5–11.1)	109 (60–197)
2–6 months after ATT	57	5.7 (4.4–7.3)	109 (42–183)
No ART	292	29.2 (26.5–32.1)	95 (47–165)

AFB: acid fast bacilli; ART: antiretroviral therapy; ATT: anti-tuberculosis treatment; CI: confidence interval; IQR: interquartile range. *cells/mm³.